Zacks: Brokerages Expect Nuvectra Corp (NVTR) to Announce -$0.65 EPS

Brokerages forecast that Nuvectra Corp (NASDAQ:NVTR) will report ($0.65) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Nuvectra’s earnings. The lowest EPS estimate is ($0.68) and the highest is ($0.62). Nuvectra reported earnings of ($0.84) per share during the same quarter last year, which would suggest a positive year over year growth rate of 22.6%. The firm is expected to issue its next quarterly earnings report on Wednesday, May 1st.

According to Zacks, analysts expect that Nuvectra will report full-year earnings of ($2.77) per share for the current financial year, with EPS estimates ranging from ($2.80) to ($2.74). For the next fiscal year, analysts anticipate that the company will post earnings of ($2.47) per share, with EPS estimates ranging from ($2.55) to ($2.39). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Nuvectra.

Nuvectra (NASDAQ:NVTR) last posted its quarterly earnings data on Thursday, February 28th. The company reported ($0.65) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.80) by $0.15. Nuvectra had a negative net margin of 91.74% and a negative return on equity of 60.14%. The company had revenue of $14.53 million during the quarter, compared to the consensus estimate of $15.58 million.

Several equities research analysts have issued reports on NVTR shares. BidaskClub cut shares of Nuvectra from a “hold” rating to a “sell” rating in a research report on Tuesday, February 26th. Raymond James decreased their price target on shares of Nuvectra from $23.00 to $18.00 and set an “outperform” rating for the company in a research note on Friday, March 1st. Zacks Investment Research upgraded Nuvectra from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a research report on Tuesday, January 1st. Finally, ValuEngine downgraded Nuvectra from a “buy” rating to a “hold” rating in a research report on Saturday, February 2nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. Nuvectra presently has an average rating of “Buy” and an average price target of $21.40.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Wells Fargo & Company MN increased its stake in Nuvectra by 16.3% during the 3rd quarter. Wells Fargo & Company MN now owns 280,945 shares of the company’s stock valued at $6,175,000 after purchasing an additional 39,327 shares in the last quarter. BlackRock Inc. boosted its position in Nuvectra by 15.9% during the 3rd quarter. BlackRock Inc. now owns 956,198 shares of the company’s stock worth $21,019,000 after acquiring an additional 130,946 shares during the period. Dimensional Fund Advisors LP boosted its position in Nuvectra by 5.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 744,170 shares of the company’s stock worth $16,357,000 after acquiring an additional 40,402 shares during the period. United Services Automobile Association purchased a new stake in shares of Nuvectra during the 3rd quarter worth about $1,152,000. Finally, GSA Capital Partners LLP purchased a new stake in shares of Nuvectra during the 3rd quarter worth about $201,000. Hedge funds and other institutional investors own 81.22% of the company’s stock.

Shares of NVTR traded down $0.46 during midday trading on Wednesday, reaching $10.15. 3,860 shares of the stock were exchanged, compared to its average volume of 157,548. Nuvectra has a 12-month low of $10.09 and a 12-month high of $25.17. The company has a debt-to-equity ratio of 0.47, a current ratio of 5.81 and a quick ratio of 5.48. The company has a market capitalization of $180.75 million, a PE ratio of -3.16 and a beta of -0.04.

Nuvectra Company Profile

Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs.

Featured Story: Put Option

Get a free copy of the Zacks research report on Nuvectra (NVTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nuvectra (NASDAQ:NVTR)

Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.